ÀÖ²¥´«Ã½ Comments on Nicotine Yield in Cigarettes and Other Products
October 1, 2025
As part of its decades-long leadership in advancing public health and reducing tobacco-related harm, ÀÖ²¥´«Ã½ submitted a comment to the US Food and Drug Administration (FDA) in response to the proposed rule .
ÀÖ²¥´«Ã½ has historically championed evidence-based tobacco control policies and views nicotine reduction as a necessary but incomplete evolution in the FDA’s regulatory framework—one that must be paired with broader product standards, enforcement, and cessation support.
Drawing on the expertise of ÀÖ²¥´«Ã½’s Tobacco and Vaping Work Group members, ÀÖ²¥´«Ã½ offered the following recommendations to strengthen the rule:
- Expand nicotine limits to include heated tobacco and other addictive products
- Clarify that flavored products are not safe cessation tools
- Prevent unauthorized marketing targeting youth
- Support research on nicotine reduction in e-cigarettes
- Implement the rule immediately, rather than delaying two years
- Publicly fund enforcement, surveillance, and cessation support
- Incentivize organizations that promote tobacco cessation
For future regulations, ÀÖ²¥´«Ã½ urges the FDA to:
- Close the synthetic nicotine loophole
- Ensure equitable access to cessation products and services
- Promote innovation in cessation therapies beyond just measuring abstinence
READ THE FULL COMMENT LETTER »
Additionally, ÀÖ²¥´«Ã½ joined more than 70 organizations by signing on to comments led by the Campaign for Tobacco-Free Kids. Aligning with ÀÖ²¥´«Ã½’s recommendations, the comment letter urges the FDA to commit to a comprehensive regulatory approach that strengthens the rule and stresses to the public, particularly young people, that any use of these products will continue to carry substantial health risks.